BriMindInvest Logo

Intuitive Surgical Inc. (ISRG) Stock Analysis 2026

Medical DevicesRobotic Surgery & Surgical Instruments
$368.27as of 2026-08-04

BriMind AI Score

Proprietary
50
Neutral
Price CAGR
16.5%
1Y Return
-26.9%
Analyst Upside
+35.1%
Rev Growth
18.5%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$323.62-12.1% potential
Bear Case
$186.56
Bull Case
$505.83
Model Confidence90%

BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

About Intuitive Surgical Inc.

Intuitive Surgical is the undisputed leader in robotic-assisted surgery, with its da Vinci surgical system installed in 9,000+ hospitals worldwide. The company's robots assist surgeons in performing minimally invasive procedures across urology (prostatectomy), gynecology (hysterectomy), general surgery (hernia repair, cholecystectomy), and thoracic surgery. Intuitive launched the next-generation da Vinci 5 system in 2024, its most significant platform upgrade in a decade.

How Intuitive Makes Money

Intuitive earns from a razor-and-blade model: system placements (~17% of revenue — da Vinci robots cost $1-2.5M each), instruments and accessories (~55% — single-use instruments consumed per procedure, $700-3,500 per procedure), and services (~28% — maintenance contracts and training). The recurring instruments and services revenue is the key to the business — once a hospital buys a robot, it generates decades of consumable revenue.

Intuitive Revenue & Profitability Breakdown

This chart shows how Intuitive's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$11.03B
Cost of Revenue
-$3.68B
Gross Profit
$7.36B66.7% margin
Operating Expenses
-$3.65B
Operating Income
$3.71B33.6% margin
Tax & Other
-$569.0M
Net Income
$3.14B28.4% margin
Gross Margin
66.7%
Operating Margin
33.6%
Net Margin
28.4%
EBITDA Margin
34.0%

Key Financial Metrics

A snapshot of the company's valuation, growth, profitability, and financial health. Key things to look at: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business — companies with strong FCF can buy back shares, pay dividends, or invest; Debt/Equity shows how leveraged the company is (high debt can be risky); Return on Equity tells you how efficiently the company generates profit from shareholders' money.

Market Cap
$126.59B
Enterprise Value
$195.26B
P/E (Trailing)
40.47
P/E (Forward)
29.27
EV / EBITDA
65.83
Price / Sales
22.91
Price / Book
11.67
Revenue
$11.03B
Revenue Growth
18.5%
Earnings Growth
26.5%
EBITDA
$2.97B
Gross Margin
66.7%
Operating Margin
33.6%
Net Margin
28.4%
Return on Equity
17.4%
Return on Assets
10.5%
Free Cash Flow
$2.62B
Total Cash
$4.51B
Total Debt
$0
Debt / Equity
0.95
Current Ratio
4.96
Quick Ratio
3.64
Beta
1.46
Dividend Yield
None
Payout Ratio
0.0%
Book Value / Share
$51.34

Wall Street Analyst Consensus

Professional analysts at investment banks set 12-month price targets after researching the company's earnings, competitive position, and industry trends. Strong Buy / Buy means the majority expect meaningful upside. Hold means analysts see fair value near the current price — not a sell signal, but limited near-term upside expected. The mean target is the average of all analyst price targets; the range shows where the most optimistic and most cautious analysts stand.

Consensus RatingBuy(28 analysts)
SellStrong Buy
Low Target$350.00-5.0%
Mean Target$477.25+29.6% upside
High Target$675.00+83.3%

Intrinsic Value Estimates for ISRG

Intrinsic value is what a stock is truly worth based on the company's fundamentals — independent of what the market currently prices it at. We use multiple models because no single formula is perfect: each captures different aspects of a business. If multiple models agree the stock is undervalued, that convergence is a stronger signal. A stock trading well below its intrinsic value may be a bargain; one far above may carry more risk.

DCF Model (10yr)
$153.23
-58.4% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
Fair Value Range
$153.23 – $153.23
Average Estimate
$153.23
Potential Downside
-58.4%

⚠️ Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

ISRG Investment Case: Bull vs Bear

Every investment has two sides. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks that could cause the investment to underperform. Good investors read both sides carefully before deciding. A strong bull case with manageable bear risks typically makes for a more compelling investment.

Bull Case (Reasons to Buy)

  • da Vinci 5 is a generational upgrade — force feedback, AI-powered insights, and improved ergonomics should accelerate adoption and expand into new procedure types.
  • Only 3-5% of addressable procedures are performed robotically — the penetration runway is enormous, particularly in general surgery and international markets.
  • Installed base of 9,000+ systems generates $6B+ in recurring instruments and services revenue — a durable, growing annuity stream.
  • First-mover advantage with 25+ years of surgeon training creates switching costs — surgeons trained on da Vinci are reluctant to switch to competing platforms.

Bear Case (Key Risks)

  • Valuation is extreme — at 60-70x forward P/E, Intuitive is priced for flawless execution over many years.
  • Competition is intensifying — Medtronic (Hugo), J&J (Ottava), and Stryker are developing surgical robots that could erode Intuitive's monopoly.
  • da Vinci 5 transition may cannibalize da Vinci Xi placements in the near term as hospitals wait for the new system.
  • Hospital capital budgets are pressured — expensive robotic systems ($1-2.5M) face scrutiny when hospital margins are thin.

What to Watch: ISRG Key Metrics

da Vinci procedure growth
da Vinci 5 system placements
Instruments & accessories revenue per procedure
Installed base growth
International market expansion

ISRG Stock — Frequently Asked Questions

Compare ISRG with Peers

ISRG vs MDTIntuitive Surgical vs Medtronic — Which Medical Device
BSX vs ISRGBoston Scientific vs Intuitive Surgical — Which MedTech
ISRG vs SYKIntuitive Surgical vs Stryker — Which MedTech Robot Sto
ISRG vs GEHCIntuitive Surgical vs GE HealthCare — Robotic Surgery v
ISRG vs NVCRIntuitive Surgical vs NovaCure — Robotic Surgery vs Ele
EDAP vs IRTCiRhythm vs Inspire Medical — Cardiac Monitoring vs Slee
ISRG vs ABTIntuitive Surgical vs Abbott — Which Medtech Stock Wins
PEN vs ISRGPenumbra vs Intuitive Surgical — Neurovascular vs Robot

ISRG — Related Investment Themes

Top Robotics Stocks8 stocks in themeTop Humanoid Robot Stocks8 stocks in theme

Unlock the Full ISRG Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
← Back to Home · Browse All Stock Analysis